# TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer

> **NCT00057720** · PHASE3 · COMPLETED · sponsor: **Telik** · enrollment: 440 (—)

## Conditions studied

- Ovarian Neoplasms

## Interventions

- **DRUG:** TLK286 HCl for injection
- **DRUG:** topotecan hydrochloride for injection
- **DRUG:** doxorubicin HCl liposome injection

## Key facts

- **NCT ID:** NCT00057720
- **Lead sponsor:** Telik
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** 2006-12
- **Final completion:** 2006-12
- **Target enrollment:** 440 (—)
- **Last updated:** 2011-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00057720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00057720, "TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00057720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*